General Information of Drug (ID: DMM19AO)

Drug Name
alkyl OMPT Drug Info
Synonyms alkyl OMPT; GTPL2913; CHEMBL3621962; [(2S)-2-methoxy-3-[(9Z)-octadec-9-en-1-yloxy]propoxy](sulfanylidene)phosphonous acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
56947064
TTD Drug ID
DMM19AO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-100842 DMDMQW0 Fibrosis GA14-GC01 Phase 2 [3]
BMS-986020 DMHMV6E Scleroderma 4A42 Phase 2 [4]
BMS-986278 DMD27RW Pulmonary fibrosis CB03.4 Phase 2 [5]
BMS-986337 DM9GC6L Pulmonary fibrosis CB03.4 Phase 1 [6]
BMS-986202 DM8TAI9 Idiopathic pulmonary fibrosis CB03.4 Preclinical [7]
LPA DMI5XR1 Discovery agent N.A. Investigative [8]
Ki16425 DMJTDK9 Discovery agent N.A. Investigative [9]
dioctanoylglycerol pyrophosphate DM0QY1V Discovery agent N.A. Investigative [10]
2-oleoyl-LPA DMN9OS1 Discovery agent N.A. Investigative [11]
dodecyl-thiophosphate DMAJVPI Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-100842 DMDMQW0 Fibrosis GA14-GC01 Phase 2 [3]
LPA DMI5XR1 Discovery agent N.A. Investigative [13]
Ki16425 DMJTDK9 Discovery agent N.A. Investigative [14]
dioctanoylglycerol pyrophosphate DM0QY1V Discovery agent N.A. Investigative [10]
2-oleoyl-LPA DMN9OS1 Discovery agent N.A. Investigative [11]
dodecyl-thiophosphate DMAJVPI Discovery agent N.A. Investigative [12]
oleoyl-thiophosphate DM1TAM9 Discovery agent N.A. Investigative [12]
VPC12249 DM6F0VR Discovery agent N.A. Investigative [15]
NAEPA DM38XWZ Discovery agent N.A. Investigative [16]
dodecylphosphate DMPCLTW Discovery agent N.A. Investigative [17]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysophosphatidate-3 receptor (LPAR3) TTE2YJR LPAR3_HUMAN Agonist [2]
Lysophosphatidic acid receptor 1 (LPAR1) TTQ6S1K LPAR1_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2913).
2 Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists. ChemMedChem. 2006 Mar;1(3):376-83.
3 Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec;8(1):e001026.
6 ClinicalTrials.gov (NCT04550195) A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety and Tolerability, and Pharmacokinetics (Including Food Effect, pH Effect and Japanese Bridging Study) of BMS-986337 Following Oral Administration in Healthy Participants. U.S.National Institutes of Health.
7 Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700.
8 Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. J Neurosci. 2010 May 26;30(21):7300-9.
9 Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol. 2012 Apr;40(4):1133-41.
10 Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001 Oct;60(4):776-84.
11 Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65.
12 Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
13 Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem. 1999 Sep 24;274(39):27776-85.
14 Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003 Oct;64(4):994-1005.
15 Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol. 2001 Dec;60(6):1173-80.
16 LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31.
17 Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42.